There exist no standards of care for patients with HCN NOS after front-line therapy has failed. Considerations include response to prior therapy, agents used front-line/not used, sites of disease, surgical options, and molecular findings of the tumor itself. Platinum/anthracycline-based therapy, car...

It would be important to ensure this tumor has been sequenced and to know whether a TERT promoter mutation has been identified. This mutation is found at very high frequency for a subset of HCN NOS which is provisionally termed as Hepatoblastoma with HCC features. These patients are intermediate in ...